Inactive Instrument

Ayala Pharmaceuticals, Inc.

Stocks

ADXS

US0076244062

Biotechnology & Medical Research

Ayala Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

Published on 04/15/2024

S&P Capital IQ

Add MarketScreener to your sources

AYALA PHARMACEUTICALS, INC.

+5.89%

Ayala Pharmaceuticals, Inc. filed its 10-K on Apr 16, 2024 for the period ending Dec 31, 2023. In this report its auditor, Kost Forer Gabbay & Kasierer, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Add MarketScreener to your sources

Latest news about Ayala Pharmaceuticals, Inc.

25-04-09	OS Therapies Finalizes Acquisition of Advaxis Assets From Ayala Pharmaceuticals	MT
25-04-08	OS Therapies Incorporated completed the acquisition of Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc..	CI
25-01-29	OS Therapies to Acquire Certain Ayala Pharmaceuticals Assets	MT
25-01-28	OS Therapies Incorporated agreed to acquire Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. for $8 million.	CI
24-04-16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-15	Ayala Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-04-15	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-03	Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024	CI
24-04-03	Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc	CI
24-03-24	Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	CI
24-02-20	Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	CI
24-02-06	Top Midday Gainers	MT
24-02-06	Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	MT
24-02-05	Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	CI
23-11-20	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Chart Ayala Pharmaceuticals, Inc.

Duration

Period

ADXS: Dynamic Chart

Company Profile

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company